BR112014017902A2 - Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose - Google Patents

Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose

Info

Publication number
BR112014017902A2
BR112014017902A2 BR112014017902A BR112014017902A BR112014017902A2 BR 112014017902 A2 BR112014017902 A2 BR 112014017902A2 BR 112014017902 A BR112014017902 A BR 112014017902A BR 112014017902 A BR112014017902 A BR 112014017902A BR 112014017902 A2 BR112014017902 A2 BR 112014017902A2
Authority
BR
Brazil
Prior art keywords
glucose metabolism
therapeutic
prophylactic agent
disorders
diseases caused
Prior art date
Application number
BR112014017902A
Other languages
English (en)
Inventor
Hisatome Ichiro
Tsujimoto Shunsuke
Shirakura Takashi
Hiramitsu Shinya
Original Assignee
Teijin Pharma Limited E National Univ Corporation Tottori Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Pharma Limited E National Univ Corporation Tottori Univ filed Critical Teijin Pharma Limited E National Univ Corporation Tottori Univ
Publication of BR112014017902A2 publication Critical patent/BR112014017902A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

AGENTE TERAPÊUTICO OU PROFILÁTICO PARA DOENÇAS CAUSADAS POR DISTÚRBIOS DO METABOLISMO DE GLICOSE. O propósito da presente invenção é prover um novo agente terapêutico ou um novo agente profilático para doenças associadas com metabolismo anormal da glicose. A presente invenção é um agente terapêutico ou um agente profilático para doenças associadas com metabolismo anormal da glicose, que compreende um composto de 2-feniltiazol representado pela fórmula (I) ou um sal farmaceuticamente aceitável do mesmo como um ingrediente ativo.
BR112014017902A 2012-01-27 2013-01-25 Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose BR112014017902A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012015351 2012-01-27
PCT/JP2013/051627 WO2013111870A1 (ja) 2012-01-27 2013-01-25 糖尿病の治療薬

Publications (1)

Publication Number Publication Date
BR112014017902A2 true BR112014017902A2 (pt) 2017-08-22

Family

ID=48873581

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017902A BR112014017902A2 (pt) 2012-01-27 2013-01-25 Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose

Country Status (15)

Country Link
US (1) US20150005506A1 (pt)
EP (1) EP2808018B1 (pt)
JP (1) JP5924699B2 (pt)
KR (1) KR20140134266A (pt)
CN (1) CN104066430A (pt)
AR (1) AR089812A1 (pt)
AU (1) AU2013212865A1 (pt)
BR (1) BR112014017902A2 (pt)
CA (1) CA2862602A1 (pt)
HK (1) HK1201209A1 (pt)
IN (1) IN2014DN05972A (pt)
MX (1) MX2014008484A (pt)
RU (1) RU2014134845A (pt)
TW (1) TW201334779A (pt)
WO (1) WO2013111870A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104628671B (zh) * 2015-02-10 2016-04-13 佛山市赛维斯医药科技有限公司 含苯基脒结构的硝基苯噻唑羧酸酰胺类化合物及用途
CN104610188B (zh) * 2015-02-10 2016-07-27 佛山市赛维斯医药科技有限公司 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途
CN104610190B (zh) * 2015-02-10 2016-08-17 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构的卤代苯基噻唑羧酸酰胺类化合物及用途
CN104628672A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含苯基脒结构的烷氧苯基噻唑羧酸酰胺类化合物及用途
CN104628673A (zh) * 2015-02-10 2015-05-20 佛山市赛维斯医药科技有限公司 一类含叔丁基脒结构的腈基苯噻唑羧酸酰胺类化合物及用途
KR102473677B1 (ko) * 2015-08-17 2022-12-02 삼성디스플레이 주식회사 액정 표시 장치
US11344539B2 (en) 2016-02-19 2022-05-31 National University Corporation Tottori University Therapeutic or prophylactic drug for dementia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100221041B1 (ko) * 1990-11-30 1999-09-15 야스이 쇼사꾸 2-아릴티아졸 유도체 및 그의 약제학적 조성물
HUP9902721A2 (hu) * 1997-11-25 1999-12-28 The Procter & Gamble Co. Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
US20050074442A1 (en) * 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
WO2006012438A2 (en) * 2004-07-21 2006-02-02 University Of Florida Research Foundation, Inc. Compositions and methods for treatment and prevention of insulin resistance
JP2009501795A (ja) * 2005-07-21 2009-01-22 ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド 高尿酸血に関連する健康状態の治療及び予防のための組成物及び方法
CA2617248C (en) 2005-08-03 2015-09-29 Tap Pharmaceutical Products, Inc. Methods for treating hypertension
CA2630639A1 (en) * 2005-11-21 2007-05-31 Tap Pharmaceutical Products, Inc. Treatment of qt interval prolongation and diseases associated therewith
JP2007210978A (ja) 2006-02-13 2007-08-23 Hiroshima Univ 耐糖能障害、ｉｉ型糖尿病、高脂血症、メタボリックシンドローム、内臓脂肪型肥満、脂肪肝または非アルコール性脂肪性肝炎の予防・治療剤
KR20160031040A (ko) 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US8084483B2 (en) * 2007-11-27 2011-12-27 Ardea Biosciences, Inc. Compounds and compositions and methods of use
DK2266989T3 (en) * 2008-03-31 2015-11-23 C&C Res Lab Heterocyclic derivatives
EP2282736B1 (en) * 2008-04-30 2015-11-11 Wellstat Therapeutics Corporation Tetrazole compounds for reducing uric acid
EP2668953A1 (en) * 2008-05-22 2013-12-04 Bristol-Myers Squibb Company Pharmaceutical compositions comprising an SGLT2 inhibitor with a supply of carbohydrate and/or an inhibitor of uric acid synthesis
CN102256488A (zh) * 2008-10-19 2011-11-23 理查德·J·约翰逊 伴随代谢失衡慢性肾病的治疗组合物和治疗方法
US20120219536A1 (en) * 2009-08-24 2012-08-30 Queensland University Of Technology Purine-targeted diagnosis and therapy of wounds
WO2011159745A1 (en) * 2010-06-16 2011-12-22 Takeda Pharmaceuticals North America, Inc. Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
JPWO2011162390A1 (ja) * 2010-06-25 2013-08-22 帝人ファーマ株式会社 徐放性高血圧および腎機能障害治療剤

Also Published As

Publication number Publication date
JP5924699B2 (ja) 2016-05-25
AR089812A1 (es) 2014-09-17
EP2808018A4 (en) 2015-07-15
WO2013111870A1 (ja) 2013-08-01
IN2014DN05972A (pt) 2015-06-26
EP2808018B1 (en) 2018-03-14
EP2808018A1 (en) 2014-12-03
CN104066430A (zh) 2014-09-24
KR20140134266A (ko) 2014-11-21
MX2014008484A (es) 2014-10-14
CA2862602A1 (en) 2013-08-01
US20150005506A1 (en) 2015-01-01
RU2014134845A (ru) 2016-03-20
JPWO2013111870A1 (ja) 2015-05-11
TW201334779A (zh) 2013-09-01
AU2013212865A1 (en) 2014-08-14
HK1201209A1 (en) 2015-08-28

Similar Documents

Publication Publication Date Title
BR112014017902A2 (pt) Agente terapêutico ou profilático para doenças causadas por distúrbios do metabolismo de glicose
BR112016000909A8 (pt) derivados piperidinil indólicos, seus usos, e combinação e composição farmacêuticas
PH12015501404A1 (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
CU20130137A7 (es) Derivados de ácido 3- fenilpropiónico ramificados y su uso
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
UY32809A (es) Compuestos y composiciones como inhibidores de cinasa s y k
BR112015011031A2 (pt) moduladores de grp40 de di-hidropirazol
BR112013019257A2 (pt) composição de androgênio para tratar uma condição oftálmica
BR112014009391A2 (pt) dosagem faseada de clopidogrel
MX2015017861A (es) Derivados de benzotiofeno como inhibidores del receptor de estrogeno.
BR112013002250A2 (pt) composto, medicamento, método para a profilaxia ou tratamento de depressão, esquisofrenia, mal de alzheimer ou distúrbio de hiperatividade e déficit de atenção, e, uso de um composto.
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
BR112014007257A2 (pt) composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal
CU24244B1 (es) Composición farmacéutica recubierta que contiene regorafenib
BR112012031580A2 (pt) derivado de tetra-hidrocarbolina
BR112015010791A2 (pt) moduladores de gpr40 de di-hidropirazol
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
BR112013019522A2 (pt) dissialil lacto-n-tetraose (dslnt) ou as variantes, os isômeros, os análogos e os derivados da mesma para prevenir ou inibir doença do intestino
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
BR112015026967A8 (pt) fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica
BR112015021990A2 (pt) moduladores de gpr120 de ácido biciclo [2.2.1]
DOP2013000305A (es) 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
BR112014029597A2 (pt) compostos de cromano

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]